Landmark trial ONTARGET?? proves telmisartan is as protective as ramipril and better tolerated in a broad high-risk cardiovascular population.From ONTARGET?? it may be concluded that telmisartan can prevent every 5th serious cardiovascular

Results of 25,620 patient study ONTARGET?? (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) presented today at the 57th Annual Scientific Session of the American College of Cardiology1 The results of the landmark ONTARGET?? Trial have proven that telmisartan, brand name MICARDIS??, a modern angiotensin II receptor blocker (ARB), is as protective as the current gold standard, ramipril, in reducing the risk of cardiovascular death, myocardial infarction, stroke, and hospitalisation for congestive heart failure in a broad cross-section of high-risk cardiovascular patients and with better tolerability.1 These cardiovascular events occurred in 16.66% of patients receiving telmisartan versus 16.46% of patients receiving ramipril.1 The relative risk (ratio of the probability of the event occurring in the telmisartan group versus the ramipril group) was 1.01, with a 95% CI of 0.94 -1.09. To view Multi-Media News Release, go to http://www.prnewswire.com/mnr/boehringeringelheim/32495/ By multivu Tags : 32585 , arb , cardiovascular , heart , micardis , multivu , myocardial , ontarget , stroke

Submission | March 31, 2008